This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
ENDP.Q Aperçu des actions
A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally.
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 2/6 |
| Dividendes | 0/6 |
Endo Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$0.0006 |
| Plus haut sur 52 semaines | US$0.08 |
| Plus bas sur 52 semaines | US$0.000001 |
| Bêta | 0.80 |
| 1Variation sur 1 mois | 50.00% |
| Variation sur 3 mois | 0% |
| Variation sur 1 an | -98.91% |
| 3Variation sur 3 ans | -99.99% |
| Variation sur 5 ans | -99.99% |
| Évolution depuis l'introduction en bourse | -100.00% |
Nouvelles et mises à jour récentes
Recent updates
Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg
Aug 16Endo International sees 23% rise on 3x higher than normal volume
Aug 03Endo outperforms defying bankruptcy fears and generic entry
Jul 25Endo weighs bankruptcy filing without opioid settlement - WSJ
Jul 12Endo International cools off, giving back some of its 85% Tuesday gain
Jun 29Endo: Stick A Fork In It
May 10Endo: About As Bad As It Gets
Mar 07Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year
Dec 16Endo: A Win In California But Equity Value Still A Question
Nov 02Endo International: Loses Vasostrict Trial
Aug 31Endo International: Hires Restructuring Advisor
Aug 20Endo International: All About Ongoing Litigation
Aug 07Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road
Jul 15Endo International: Bankruptcy Seems Like The Only Practical Option
Jun 30Endo International wins FDA approval for Micafungin new formulation
Jun 17Endo International plc 2021 Q1 - Results - Earnings Call Presentation
May 07Radius Health partners with Endo unit for abaloparatide in Canada
Jan 05Rendement pour les actionnaires
| ENDP.Q | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | 0% | 0.3% | 0.3% |
| 1Y | -98.9% | 23.6% | 38.3% |
Rendement vs Industrie: ENDP.Q underperformed the US Pharmaceuticals industry which returned 12.5% over the past year.
Rendement vs marché: ENDP.Q underperformed the US Market which returned 22.8% over the past year.
Volatilité des prix
| ENDP.Q volatility | |
|---|---|
| ENDP.Q Average Weekly Movement | 207.3% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Cours de l'action stable: ENDP.Q's share price has been volatile over the past 3 months.
Volatilité au fil du temps: ENDP.Q's weekly volatility has increased from 125% to 207% over the past year.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1997 | 2,931 | Blaise Coleman | www.endo.com |
Endo Inc. Résumé des fondamentaux
| ENDP.Q statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$141.13k |
| Bénéfices(TTM) | -US$2.45b |
| Recettes(TTM) | US$2.01b |
0.0x
Ratio P/S0.0x
Ratio P/ELe site ENDP.Q est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ENDP.Q compte de résultat (TTM) | |
|---|---|
| Recettes | US$2.01b |
| Coût des recettes | US$941.90m |
| Marge brute | US$1.07b |
| Autres dépenses | US$3.52b |
| Les revenus | -US$2.45b |
Derniers bénéfices déclarés
Dec 31, 2023
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -10.41 |
| Marge brute | 53.17% |
| Marge bénéficiaire nette | -121.69% |
| Ratio dettes/capitaux propres | -123.5% |
Quelles ont été les performances à long terme de ENDP.Q?
Voir les performances historiques et les comparaisons